ICAM-1 K469E polymorphism, increased risk of neurocysticercosis occurrence and immunopathological defect

CC BY-NC-ND 4.0 · Arq Neuropsiquiatr 2017; 75(09): 681
DOI: 10.1590/0004-282X20170100

OPINIONS

Polimorfismo ICAM-1 K469E, aumento do risco de ocorrência de neurocisticercose e defeito imunopatológico

Authors

References
1 Ramirez-Bermudez J, Higuera-Calleja J, Espinola-Nadurille M, Corona T. Neuropsychiatric disorders in patients with neurocysticercosis. Asia Pac Psychiatry. 2017;9(2). https://doi.org/10.1111/appy.12250
2 Silva HM, Vinaud MC, Lino Júnior RS. Experimental neurocysticercosis: absence of IL-4 induces lower encephalitis. Arq Neuropsiquiatr. 2017;75(2):96-102. https://doi.org/10.1590/0004-282X20160194
3 Arora N, Tripathi S, Sao R, Mondal P, Mishra A, Prasad A. Molecular neuro-pathomechanism of neurocysticercosis: how host genetic factors influence disease susceptibility. Mol Neurobiol. 2017 Jan 13. https://doi.org/10.1007/s12035-016-0373-6
4 Singh A, Singh AK, Singh SK, Paliwal VK, Gupta RK, Prasad KN. Association of ICAM-1 K469E polymorphism with neurocysticercosis. J Neuroimmunol. 2014;276(1-2):166-71. https://doi.org/10.1016/j.jneuroim.2014.07.018
5 Joob B, Wiwanitkit V.HSD11B1 rs846908 polymorphisms and tacrolimus concentrations: quantum chemical analysis and implication in patients with renal transplantation. J Nephropharmacol. 2016;6(1):19-20
6 Wiwanitkit V. An explanation in nanostructure level based on the view of energy change for G333d mutation relating to drug resistance in HIV-1 reverse transcriptase. Indian J Med Microbiol. 2008;26(2):202-3
7 Berger RB1, Blackwell NM, Lass JH, Diaconu E, Pearlman E.IL-4 and IL-13 regulation of ICAM-1 expression and eosinophil recruitment in Onchocerca volvulus keratitis. Invest Ophthalmol Vis Sci. 2002;43(9):2992-7.